Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV uninfected women who are in good general health.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will last 24 weeks, with an additional 10 weeks of follow-up for participants with chronic hepatitis B virus (HBV) infection. Participants will be randomly assigned to one of four arms. Arm A participants will insert a vaginal tenofovir 1% gel two hours prior to vaginal intercourse for a maximum of two daily applications. Arm B participants will insert a vaginal placebo gel two hours prior to vaginal intercourse for a maximum of two daily applications. Arm C participants will insert a vaginal tenofovir 1% gel once daily at bedtime or during the longest period of daily rest. Arm D participants will insert a vaginal placebo gel once daily at bedtime or during the longest period of daily rest.
A medical and menstrual history update, pregnancy test, HIV and sexually transmitted infections (STI) risk reduction counseling, and interview to assess behaviors toward vaginal gel use will occur during all study visits. HIV/STI counseling and testing, urinalysis, and blood collection will occur at study entry and at Week 24. Pelvic exam with colposcopy and vaginal swab collection will occur at study entry and Weeks 4, 12, and 24. For participants with chronic HBV, additional blood will be collected to monitor hepatitis B infection at study entry and Weeks 12, 24, 28, 32, and 36.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1% tenofovir gel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good general health
* Sexually active
* Willing to use acceptable methods of contraception, including male latex condoms for all acts of intercourse
* Willing to undergo all study-related assessments and adhere to the requirements of the study
Exclusion Criteria
* Hysterectomy
* Abnormal screening results for several gynecologic exams
* Taking or planning to take tenofovir, adefovir, or any other medication for chronic HBV infection
* History of latex allergy
* History of adverse reaction to tenofovir or adefovir
* Use of a diaphragm or spermicide for contraception
* Prior participation in the study
* Prior participation in any vaginal microbicide, spermicide, or other drug study within 30 days of study entry
* Gynecologic surgical procedure within 90 days of study entry
* Illicit injection drug use within 12 months of study entry
* History of vaginal intercourse more than an average of two times per day in the two weeks prior to study screening
* Any other criteria that, in the investigator's opinion, may interfere with the study
* Current pregnancy or previous pregnancy within 90 days of study entry
* Breastfeeding
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute on Drug Abuse (NIDA)
NIH
National Institute of Mental Health (NIMH)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Hillier, PhD
Role: STUDY_CHAIR
Department of Obstetrics and Gynecology and Reproductive Sciences, Magee-Women's Hospital
Jessica Justman, MD
Role: STUDY_CHAIR
Bronx-Lebanon Hospital Center
Smita N. Joshi, MBBS
Role: STUDY_CHAIR
National AIDS Research Institute (NARI)
Craig Hoesley, MD
Role: STUDY_CHAIR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Microbicide CRS
Birmingham, Alabama, United States
Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS)
The Bronx, New York, United States
NARI Arogya Aadhar Clinic CRS
Pune, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, Mwafulirwa L, Khumalo-Sakutukwa G, Celentano DD. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004 Jul;94(7):1159-64. doi: 10.2105/ajph.94.7.1159.
D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374.
Mantell JE, Myer L, Carballo-Dieguez A, Stein Z, Ramjee G, Morar NS, Harrison PF. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005 Jan;60(2):319-30. doi: 10.1016/j.socscimed.2004.05.011.
Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006 Feb 28;20(4):543-51. doi: 10.1097/01.aids.0000210608.70762.c3.
Van Damme L. Clinical microbicide research: an overview. Trop Med Int Health. 2004 Dec;9(12):1290-6. doi: 10.1111/j.1365-3156.2004.01338.x.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for the Alliance for Microbicide Development Web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10145
Identifier Type: REGISTRY
Identifier Source: secondary_id
HPTN 059
Identifier Type: -
Identifier Source: org_study_id